We actively collaborate with companies and academics to tailor our brain shuttles for drug delivery of specific payloads and diseases. Through extensive optimization of multiple shuttle-drug combinations in vitro and in vivo, we are developing safe and effective precision medicines for brain diseases.
- Payloads: Therapeutic antibodies, enzymes, oligonucleotide drugs, and gene therapies.
- Diseases: Alzheimer’s disease, Parkinson’s disease, Amyotrophic lateral sclerosis (ALS) / Frontotemporal dementia, and brain enzyme deficiency disorders.
License and Collaboration
We provide a license and focused collaboration to aid company or academic collaborator in optimizing design and brain delivery of your therapeutic.
Co-development
We work closely with company or academic partner to design, develop, test and optimize shuttle drug fusion molecules for specific brain diseases. This could involve seeking grants and other funding together, and other models of collaboration to advance fusion drugs to IND.